AXDX - Accelerate Diagnostics GAAP EPS of -$0.76 in-line revenue of $12.75M beats by $0.1M
2023-03-29 16:16:37 ET
- Accelerate Diagnostics press release ( NASDAQ: AXDX ): FY GAAP EPS of -$0.76 in-line.
- Revenue of $12.75M (+8.2% Y/Y) beats by $0.1M .
- Gross margin was 26% year-to-date, compared to an adjusted gross margin of 35% for the same period of the prior year, excluding non-cash adjustments for inventory impairment. The overall decline in gross margins resulted from ongoing pandemic-related impacts to manufacturing costs and other factors.
- Added 3 contracted instruments and brought 5 instruments live in the U.S. in the quarter.
- Ended the fourth quarter with 328 U.S. clinically live and revenue-generating instruments, with another 69 U.S. contracted instruments in the process of being implemented and not yet revenue-generating.
For further details see:
Accelerate Diagnostics GAAP EPS of -$0.76 in-line, revenue of $12.75M beats by $0.1M